Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vector-Medica is a Russian biotechnology company based in the Koltsovo science city, specializing in the development and production of antiviral and immunomodulatory drugs. The company is a leader in liposomal technology, which it utilizes to enhance the delivery and efficacy of recombinant proteins, most notably interferons. Its flagship product, Lipint, represents a significant advancement as an oral liposomal interferon alpha-2b, providing a non-invasive alternative to traditional injectable therapies for hepatitis and other viral infections. Vector-Medica operates modern, GMP-certified manufacturing facilities and maintains a robust portfolio of products targeting infectious diseases and oncology. The company's origins are closely linked to the State Research Center of Virology and Biotechnology "Vector," one of the world's leading virology institutes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vector-Medica.